SLC11A2 and Parkinson disease: Previous studies have shown that ALA alleviates the motor deficits in Parkinson’s disease (PD) models by regulating iron metabolism, including the upregulation of ferritin heavy chain (FTH1) and ferroportin (FPN), as well as the downregulation of divalent metal transporter 1 (DMT1).